In-depth guides
Structured explainers bring together the questions people commonly have about ibogaine, substance use disorders, mechanisms, uncertainty, and safety. For the scope behind that work, see Eburna’s independent resource mission.
Independent information services
Services
Guides, comparisons, and research summaries for people trying to understand the anti addictive properties of ibogaine without overstating promise or minimizing risk.
A clearer way to approach a complex subject.
Eburna is an independent resource on ibogaine’s potential role in substance use disorders, its evidence limits, legal context, and serious safety considerations. Our main resource on ibogaine and addiction evidence begins with uncertainty rather than certainty, because the topic asks for careful reading and context.
Information designed for deliberate research.
These are informational offerings, not medical or clinical services. They are intended to help readers locate the important questions, distinguish evidence from claims, and understand why safety belongs in any discussion of ibogaine.
Research summaries
Research summaries separate preliminary findings from conclusions that would require stronger evidence. Ibogaine is a naturally occurring psychoactive alkaloid associated with the Tabernanthe iboga plant, but a compound’s origin does not settle questions of effectiveness or safety.
Comparisons and context
Comparative pages place addiction-focused questions alongside adjacent topics without treating them as interchangeable. Readers looking across neurological concerns can consider the context collected at ibogaine and dementia questions and Alzheimer’s-focused material.
Decision frameworks
Plain-language frameworks help readers identify the questions that matter before accepting a broad claim: what was studied, for whom, under what conditions, and with what limits. The anti-addiction evidence overview is one starting point for following that line of inquiry.
Evidence with boundaries
Safety is not a footnote.
Any account of possible anti-addictive properties needs to include serious safety considerations. The U.S. Drug Enforcement Administration lists ibogaine as a Schedule I controlled substance in the United States, as shown in its drug scheduling information.
Our glossary and FAQ collections are designed to make complex terms easier to follow while retaining the limits of what is known. Related neurological topics are also considered through material on ibogaine and ALS, brain de-aging discussions, and a distinct brain aging reference point.
- Questions that distinguish a biological mechanism from a demonstrated outcome
- Context for legal status, reported risks, and evidence limitations
- Definitions that keep technical language accessible without flattening complexity
“Evidence before claims, safety awareness before reassurance, and plain language without false simplicity.”
Frequently asked questions
What these services are for.
What kind of information does Eburna provide?
Eburna provides guides, comparisons, research summaries, decision frameworks, glossary material, and FAQ collections. The emphasis is on helping people understand the evolving evidence landscape around ibogaine and substance use treatment questions.
Does information about ibogaine replace medical advice?
No. This resource is not medical or legal advice. The U.S. Food and Drug Administration explains that it evaluates medical products through a formal drug development and approval process; independent informational material does not replace individualized professional care or legal guidance.
Why present comparisons beside addiction-focused material?
Comparisons can show where a claim is specific, where it is being generalized, and where evidence may be absent. They are not a promise of benefit for addiction, dementia, Alzheimer’s disease, ALS, or brain aging.
Begin with the fundamentals
A measured starting point for researching ibogaine.
Use the central resource to orient yourself to addiction evidence, uncertainty, legal context, and serious safety considerations before drawing conclusions.
State of the evidence